Abstract：Objective: To investigate the expression of KI67 protein in ovarian cancer and its correlation with clinicopathological features and prognosis. Methods: 60 patients with ovarian cancer admitted to our hospital from January 2013 to December 2014 were selected as the study subjects, and 30 patients with benign ovarian tumors treated in the same period were selected as the control group. The expression of KI67 protein in different ovarian tissues was measured by immunofluorescence labeling, and its correlation with clinicopathological characteristics and prognosis was further analyzed. Result: The expression level of KI67 protein in ovarian cancer tissue was higher than that in benign ovarian tumor tissue and normal ovarian tissue, while that in benign ovarian tumor tissue was higher than that in normal ovarian tissue (P<0.05). The expression level of KI67 protein in ovarian cancer tissues of patients with ovarian cancer was higher than that of patients with tumor diameter > 3cm than that of patients with tumor diameter > 3cm, TNM stage > (III+ IV) than (I+ II), low differentiation than high and moderate differentiation (P<0.05). Within 4 years, the expression level of KI67 protein in the death group was higher than that in the survival group (P<0.05). Conclusion: KI67 protein is highly expressed in ovarian cancer tissues and is associated with the occurrence, development and prognosis of ovarian cancer.
马春艳. 卵巢癌组织中KI67蛋白的表达及临床病理特征与预后的相关性[J]. 河北医学, 2019, 25(7): 1102-1104.
MA Chunyan. Expression of KI67 Protein in Ovarian Cancer and its Correlation with Clinicopathological Features and Prognosis. HeBei Med, 2019, 25(7): 1102-1104.
[1] 赫慧,毕芳芳,杨清.MSLN、HE4和Ki67在高级别浆液性卵巢癌组织中的表达及意义[J].现代肿瘤医学,2017,25(20):3290~3294. [2] 于歌,孙佳宁,冯晓玲.上皮性卵巢肿瘤组织中PSMD10、Ki67的表达及其临床病理意义[J].实用肿瘤学杂志,2017,31(2):112~116. [3] 宋莉莉,郗彦凤.检测P53、Ki67的表达水平在预估上皮性卵巢癌患者生存期的价值分析[J].当代医药论丛,2016,14(6):24~25. [4] 陈梦云,张翠翠,轩菡,等.Ki67在肿瘤中的表达及其临床指导意义[J].现代生物医学进展,2015,15(16):3193~3196. [5] Loibl S, de la Pena L, Nekljudova V, et al. Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE) [J]. Eur Cancer,2017,85(11):133~145. [6] Costa R, Zaman S, Sharpe S, et al. A brief report of toxicity end points of HER2 vaccines for the treatment of patients with HER2+ breast cancer[J]. Drug Des Devel Ther,2019, 13(1):309~316.
2019, Vol. 25 
冀公网安备13080202000677号